

Critical Path for Parkinson's Celebrates Foundational 10-year Milestone

Critical Path Institute's Critical Path for Parkinson's consortium is celebrating a significant 10-year milestone today. The genesis of what CPP is today took place in London during a pivotal meeting on May 1-2 in 2014 thanks to Parkinson's UK. At this meeting organized by Parkinson's UK, multiple stakeholders gathered to highlight how together we might transform the richness of data that exist around the world into actionable solutions to accelerate PD drug development. The meeting resulted in a roadmap publication that included all attendees as co-authors, which set into motion our exciting workplan. CPP has grown to be a vibrant and impactful initiative focused on addressing measurement gaps in Parkinson's drug development.

Today, CPP is leading innovative partnerships centered around patient-focused drug development, model-informed drug development, biomarkers and digital health technologies. CPP consists of industry partners spanning small biotechs to large companies advancing promising therapies to patients. On behalf of C-Path we recognize the leadership of Parkinson's UK in their foundational support of CPP and the growing alliances with The Michael J. Fox Foundation and eight other nonprofit organizations.

Reach out to us to learn more about CPP as we continue to raise the need for data-driven solutions that accelerate much needed treatments. Learn more, here: <https://c-path.org/program/critical-path-for-parkinsons/>

Below, you will find the abstract and a link to the publication from the seminal meeting a decade ago:

Abstract

Parkinson's disease is a complex heterogeneous disorder with urgent need for disease-modifying therapies. Progress in successful therapeutic approaches for PD will require an unprecedented level of collaboration. At a workshop hosted by Parkinson's UK and co-organized by Critical Path Institute's (C-Path) Coalition Against Major Diseases (CAMD) Consortiums, investigators from industry, academia, government and regulatory agencies agreed on the need for sharing of data to enable future success. Government agencies included EMA, FDA, NINDS/NIH and IMI (Innovative Medicines Initiative). Emerging discoveries in new biomarkers and genetic endophenotypes are contributing to our understanding of the underlying pathophysiology of PD. In parallel there is growing recognition that early intervention will be key for successful treatments aimed at disease modification. At present, there is a lack of a comprehensive understanding of disease progression and the many factors that contribute to disease progression heterogeneity. Novel therapeutic targets and trial designs that incorporate existing and new biomarkers to evaluate drug effects independently and in combination are required. The integration of robust clinical data sets is viewed as a powerful approach to hasten medical discovery and therapies, as is being realized across diverse disease conditions employing big data analytics for healthcare. The application of lessons learned from parallel efforts is critical to identify barriers and enable a viable path forward. A roadmap is presented for a regulatory, academic, industry and advocacy driven integrated initiative that aims to facilitate and streamline new drug trials and registrations in Parkinson's disease.

[Read the full publication in its original format on PubMed here.](#)